Cook Steven L. sold $325K of OMDA

Cook Steven L. (Chief Financial Officer) sold 17,950 shares of Omada Health, Inc. (OMDA) at $18.13 ($0.33M total) on 2026-06-22 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Cook Steven L.
Published Jun 24, 2026, 8:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 24, 2026, 8:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OMDA
Neutral
medium confidence
Mentioned
$OMDA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OMDANeutralLow
01

Why it matters

This provides a fresh, primary-source datapoint on insider activity (CFO open-market sale) but does not include new fundamentals (guidance, trials, deals) or enforcement/regulatory developments.

02

Market read

Traders may briefly reassess sentiment around OMDA due to insider selling, but the 10b5-1 pre-arrangement limits the actionable signal.

03

What to watch

The sale size (~$325K) is modest relative to typical institutional flows, and the 10b5-1 structure suggests the timing was pre-set rather than information-driven.

Relevance 3/10Novelty 5/10Timing: after-hours/filing update (Form 4 filed 2026-06-24)

Background

The article is a SEC Form 4 insider transaction disclosure for Omada Health, Inc.

Company-level read

Ticker impact

$OMDANeutralMedium confidence
Context

Omada Health CFO Steven L. Cook sold 17,950 shares (~$325.4K) on 2026-06-22 under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this Form 4 sale.

Evidence & confidence

The filing is a disclosed open-market sale by the CFO, explicitly tied to a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Minimal; this is company-specific insider transaction with no sector-wide datapoint.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can still coincide with internal caution; traders may watch for follow-on selling or other insider actions.

Key entities

  • Omada Health, Inc.

    Subject of the Form 4 insider transaction; CFO Steven L. Cook sold shares under a 10b5-1 plan.

  • Steven L. Cook

    Chief Financial Officer; executed an open-market sale of 17,950 shares at $18.1278 on 2026-06-22.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$OMDAHigh

Omada Health Earnings Call Signals Strong Growth Ahead

Omada Health (OMDA) reported Q3 revenue of $91M, up 34% YoY, with GAAP net income of $7M vs. a loss last year. Adjusted EBITDA rose to $12M. Management raised 2026 revenue guidance to $344M-$346M and adjusted EBITDA to $32M-$34M, citing strong demand for diabetes and hypertension programs. The company expects Q4 seasonality and GLP-1 coverage uncertainty.

$OMDAMed

What Omada Health (OMDA) Said on Its Q3 Earnings Call

Omada Health (OMDA) expects Q4 revenue to decline due to seasonal factors, with adjusted EBITDA also moderating. The company ended Q3 with $243M in cash and no debt. CEO Sean Duffy will transition to executive chair in 2027, with Shao taking over as CEO. Omada's GLP-1 Care Track showed a 6% average weight loss at 12 weeks, according to peer-reviewed research.

$OMDAMedAI 8/10

Omada Health Inc (OMDA) (Q3 2026) Earnings Call Highlights: Record Revenue, Membership

Omada Health Inc (OMDA) reported record revenue and membership growth in Q3 2026. However, new enrollments are expected to decline in Q4 due to seasonality and tough comparisons. GLP-1 market dynamics and rising healthcare costs create uncertainty for 2027. Adjusted EBITDA is expected to moderate due to increased R&D and staffing. The company aims for 20%+ growth in 2027 through expanding covered lives, improving enrollment rates, and increasing engagement.